In this interview, Sebastiaan J. Trietsch, Chief Technology Officer at MIMETAS, discusses how microphysiological systems are ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

The development of long-acting drug depots represents a significant advancement in pharmaceutical technology, offering ...

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited efficacy and only in mild stages of the disease.

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.